Elite Capital is a venture capital / private equity firm targeting life sciences companies; we have both a RMB and a USD fund.
Elite Capital USD Fund targets innovative U.S. medical device and biopharma companies with strong U.S. and China market opportunities. In addition to capital, Elite Capital could provide accelerated, cost-effective development of the China market. Support services include China management team recruitment, Chinese clinical trials, CFDA regulatory filing and approval guidance, strategic planning and business development.
Elite Capital RMB Fund targets China domestic life sciences companies. We target both larger companies at the cusp of IPO, as well as smaller companies with strong product portfolio and great upside. In addition, the RMB fund will provide capital to incubate leading technologies and products from overseas in China.
Elite Capital is unique in our network of industry relationships and know-how. Our senior team members are former pharmaceutical and healthcare industry executives who now focus their time on identifying productive investment opportunities. Through our industry network and strong relationships, Elite Capital can find quality investment opportunities. We know the target company, its markets, culture, and external needs. In turn the target company knows it can trust Elite Capital.
Elite Capital’s investments are sourced via Elite Consulting’s client base (1200 medical companies) and Elite Capital’s collaboration with Domain Associates, a leading U.S. biomedical venture fund that has invested nearly $3 billion over 30 years in 250 innovative pharmaceutical and med-tech companies.
Elite Consulting, founded in Beijing in 1998, serves domestic and international pharmaceutical and medical device companies in China, USA, Europe, and Japan. Elite Consulting excels at implementation of turnaround, new market growth strategies, and accelerated CFDA regulatory approvals.
In 2010, Hony Capital and Elite Capital’s co-invested $30M in Dihon Pharma. Elite conducted commercial due diligence, placed the General Manager for Sales and Marketing in Dihon, and helped with corporate strategic planning process. In 2014, Elite exited at 4.7x return ($586M M&A to Bayer AG).
In March 2014, Elite Capital co-invested $6.5M with Domain Associates through joint venture DomainElite in SMART Medical, an Israeli company that develops innovative products in gastrointestinal endoscopy. Elite is currently handling the Chinese regulatory affairs on behalf of SMART Medical.
In October 2014, Elite Capital co-invested $4M with Domain Associates through joint venture DomainElite for the China registration of Sequent Medical's products in China. Elite is currently handling the Chinese regulatory affairs for Sequent's innovative catheter-based neurovascular technologies.
In October 2015, Elite Capital co-lead the $80M investment in Baiyang Pharma with Sequoia Capital, with Highlight Capital and Legend Capital also investing. For the investment, Elite gained a seat on the Baiyang's Board of Directors.
17 years of experience in China as a healthcare executive and pharmaceutical industry consultant. President Asia Pacific for First Databank (Hearst Corp); Corporate Executive for UnitedHealthcare International (Hong Kong). Ten years experience in pharmaceutical and medical device marketing research and management consulting (The Wilkerson Group, New York; Strategic Marketing Asia Beijing). Four years biomedical M&A financial advisory (Elite Capital Advisors)
27 years of senior executive experience in China pharmaceutical industry. Leadership positions in China medical & regulatory affairs at Novartis, Sanofi, J&J, and Livson. At Elite, five years of financial advisory in pharmaceutical and medtech industry, 10 years of experience in management consulting to the China biomedical industry
24 years of senior executive experience in China. As Founder/CEO of BabyCare Ltd. in Beijing (sold to USANA, NYSE:USNA), grew China business from zero to $350M revenue and 250,000 distributors. Founder of Yaolan.com, a leading parenting Internet media company with 12 million active registered users. Prior was Managing Director Wella China (haircare); Sales & Marketing Director SmithKline China (GSK); Vice Chair of AmCham China (American Chamber of Commerce); YPO (Young Presidents Organization) Beijing Chapter Chair
Over 22 years of experience in marketing management, strategy consulting and market research in China pharmaceutical industry. Led and participated in nearly one hundred projects, focusing on China growth strategy, opportunity assessment and commercial due diligence. Has worked as a consultant with top multinational companies, including Novartis, Roche and Bayer, as well as top PE investors, including Blackstone, Morgan Stanley and the Carlyle Group
Over 20 years of senior executive in the Chinese pharmaceutical industry. Senior Vice President Beijing Double Crane, CFO CSPC, General Manager Shijiazhuang Siyao
24 years of experience in the China healthcare industry, co-founded two in vitro diagnostics (POCT and molecular diagnostics) companies in the last two years
10 years of experience as an investment professional focusing on the Chinese healthcare industry. Management and participated in various deals at Citic Capital, GGV Capital, and Greenwood Asset
Extensive experience in M&A advisory in China pharmaceutical industry. Currently serves as the Vice President of TCM Association, Vice President of China OTC Association, Vice President for Pharmacology Committee of World TCM Association, and expert for National Development and Reform Commission. Formerly served as senior executives for Lizhu Pharma, Shanghai Parhma, Dongrui Pharma, and Shineway Pharma
Over 20 years of senior executive experience in charge of marketing and sales in the Chinese pharmaceutical industry. Currently serves as the General Manager at Changbaishan Pharma, previously held senior executive positions in Pfizer, Janssen, Harbin Gloria, Shijiazhuang OE Pharma, and TopSun Technology
18 years of experience in life science and medical device investment and consulting. Partner at Domain Associates
Over 20 years of experience in the life sciences industry. Possesses a unique skill set having worked in venture capital, business development, strategy, banking and management consulting. Formerly partner in Bay City Capital and Delphi Venture, and served in senior executive positions in Pfizer and WuxiApptec
8 years of business development experience in pharmaceutical and medical device industry. Extensive industry connections in Israel and Europe